SCHEDULE: FMR LLC Boosts Stake in Cytokinetics to 10.9%

FMR LLC and Abigail P. Johnson have reported an aggregate beneficial ownership of 10.9% of Cytokinetics Inc.'s common stock as of July 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively hold 13,101,596.22 shares of Cytokinetics Inc. common stock.
• This represents 10.9% of the total outstanding common stock.
• FMR LLC has sole voting power over 12,747,497.94 shares and sole dispositive power over 13,101,596.22 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Abigail P. Johnson, as a Director, Chairman, and Chief Executive Officer of FMR LLC, is part of the Johnson family group that holds 49% of FMR LLC's voting power through Series B voting common shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant and passive institutional investment, which is generally positive as it signals confidence from a major financial entity. No negative information is presented.

Positives

• Significant institutional investment from FMR LLC, a major asset manager, indicating confidence in Cytokinetics Inc.'s long-term prospects.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, long-term investment perspective.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates a significant passive investment by a major financial institution in Cytokinetics Inc., a biotechnology company. Such investments are common in the biotech sector, where institutional capital plays a crucial role in funding research, development, and commercialization efforts. The substantial stake suggests FMR LLC's belief in the long-term potential of Cytokinetics' pipeline or market position.

Comparison to Industry Standards

• A 10.9% stake by a major institutional investor like FMR LLC is a substantial position, often seen as a vote of confidence in a company's long-term prospects, especially in the volatile biotechnology sector.
• Compared to other institutional holdings in similar-sized biotech firms, this level of ownership by a single entity (or related group) is significant and can provide a degree of stability to the shareholder base.
• The filing's nature as a Schedule 13G indicates a passive investment, which aligns with standard practices for large asset managers who typically do not seek to influence control unless they file a Schedule 13D.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional backing, potentially leading to greater share price stability.
• Management: Validation of company strategy and operations through a large, passive investment.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to file amendments to Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by 1% or more).

Key Dates

Recommendation

The filing indicates a significant and passive institutional investment by FMR LLC in Cytokinetics Inc., representing 10.9% of the common stock. While this is a positive signal of confidence from a major asset manager, a Schedule 13G filing primarily discloses ownership and does not provide new financial performance data, strategic updates, or operational insights that would warrant a change in fundamental investment thesis. Therefore, it reinforces a 'hold' position for existing investors, suggesting continued confidence without providing new catalysts for a 'buy' or 'sell' decision.

Keywords

Cytokinetics Inc, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing, Schedule 13G